Alimera to present Iluvien Stage 3 clinical trial data at AAO annual meeting Alimera Sciences.
Alimera is pleased to share details of the Iluvien FAME study at this venue, the most crucial ophthalmology meeting of the year probably, said Dan Myers, Alimera president and CEO. We believe the mix of low dose and lengthy duration makes Iluvien a much anticipated potential treatment for DME. Alimera submitted the Iluvien New Drug Application to the U.S. June 30 Food and Drug Administration on, 2010, and based on receipt of Concern Review position in August, anticipates a communication concerning the NDA by the finish of the year. In addition, July 5 Alimera submitted a Advertising Authorization Application on, 2010 to the Healthcare and Medicines products Regulatory Agency in the United Kingdom.In addition to the new monitor on data security, various other tracks being presented at Bio-IT World Meeting & Expo consist of: IT Infrastructure – Equipment: Big Data Solutions and End-User Perspectives – networking infrastructures, integrated storage and computing platforms and solutions, as well as analytics. Software Development: Technology and Applications for Handling and Posting Data – data handling, systems and workflows integration activities.